186 related articles for article (PubMed ID: 33899675)
1. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC-MS/MS.
Wang S; Xia M; Wang Y; Lu Z; Geng P; Dai D; Zhou Y; Wu Q
Thorac Cancer; 2023 May; 14(14):1276-1285. PubMed ID: 36973912
[TBL] [Abstract][Full Text] [Related]
3. Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib
Zhou S; Zhao FL; Wang SH; Wang YR; Hong Y; Zhou Q; Geng PW; Luo QF; Cai JP; Dai DP
Pharm Biol; 2023 Dec; 61(1):356-361. PubMed ID: 36728978
[TBL] [Abstract][Full Text] [Related]
4. Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.
Shen J; Wang B; Wang S; Chen F; Meng D; Jiang H; Zhou Y; Geng P; Zhou Q; Liu B
Drug Des Devel Ther; 2020; 14():2199-2206. PubMed ID: 32581516
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
Han M; Zhang X; Ye Z; Wang J; Kong Q; Hu X; Qian J; Cai J; Hu G
Chem Res Toxicol; 2022 Feb; 35(2):265-274. PubMed ID: 34936353
[TBL] [Abstract][Full Text] [Related]
6. Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes
Wang J; Chen F; Jiang H; Xu J; Meng D; Geng P; Dai D; Hu J; Zhou Y; Zhou Q; Wang S
Front Pharmacol; 2020; 11():593518. PubMed ID: 33746741
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS.
Wen J; Bao SS; Zhang BW; Liu TH; Ou-Yang QG; Cai JP; Zhou HY
Drug Dev Ind Pharm; 2019 Jan; 45(1):27-31. PubMed ID: 30156133
[TBL] [Abstract][Full Text] [Related]
8. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
[TBL] [Abstract][Full Text] [Related]
9. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.
Zhan YY; Liang BQ; Li XY; Gu EM; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):439-44. PubMed ID: 26391142
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
Deng G; Liu W; Ma C; Rong X; Zhang Y; Wang Y; Wu C; Cao N; Ding W; Guan H; Cheng X; Wang C
J Ethnopharmacol; 2019 May; 236():288-301. PubMed ID: 30872168
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.
Zhang Y; Liu YN; Xie S; Xu X; Xu RA
Pharm Biol; 2022 Dec; 60(1):621-626. PubMed ID: 35289238
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
13. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Qiu X; Lin Q; Ning Z; Qian X; Li P; Ye L; Xie S
J Pharm Biomed Anal; 2019 Mar; 166():66-70. PubMed ID: 30612075
[TBL] [Abstract][Full Text] [Related]
14. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.
Lin QM; Pang NH; Li YH; Huang HL; Zhang XD; Hu GX; Wang ZS
Chem Biol Interact; 2019 Sep; 310():108744. PubMed ID: 31299239
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
17. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats.
Wang R; Zhang H; Sun S; Wang Y; Chai Y; Yuan Y
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):825-833. PubMed ID: 26650374
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer.
Feng X; Ding Y; Zhang P; Fu Q; Zhang L; Zheng H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122940. PubMed ID: 34564058
[TBL] [Abstract][Full Text] [Related]
20. Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.
Mudunuru J; Ren C; Taft DR; Maniar M
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):531-538. PubMed ID: 30701428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
